ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Top Page
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
(1541)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$4.50
▼(-26.83% Downside)
Action:ReiteratedDate:01/22/26
The score is driven primarily by weak financial performance—persistent losses and negative operating cash flow with no free cash flow—creating elevated execution and liquidity risk. Technicals also remain bearish with the stock trading below key moving averages and a negative MACD, though oversold indicators modestly temper the downside. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Robust revenue growth
Extraordinary reported revenue growth indicates strong market demand and successful commercialization progress for its immuno‑oncology offerings. Sustained top‑line expansion can create optionality to fund trials, attract partners, and scale commercial operations if margins improve.
Negative Factors
Negative operating cash flow and no free cash flow
Persistent negative operating cash flow and zero free cash flow erode financial runway and force repeated external financing. That elevates dilution and constrains the company’s ability to internally fund trials, manufacture, and commercial launch activities over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust revenue growth
Extraordinary reported revenue growth indicates strong market demand and successful commercialization progress for its immuno‑oncology offerings. Sustained top‑line expansion can create optionality to fund trials, attract partners, and scale commercial operations if margins improve.
Read all positive factors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.88B
Dividend YieldN/A
Average Volume (3M)4.65M
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth29639.67%
EPS Growth23.30%
CountryHK
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding420,477,300
10 Day Avg. Volume5,424,202
30 Day Avg. Volume4,650,789
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.69
Price to Sales (P/S)24.65
P/FCF Ratio-13.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.21
Revenue Forecast (FY)HK$122.00M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Business Overview & Revenue Model
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic synd...
How the Company Makes Money
ImmuneOnco generates revenue through several key channels: first, by developing and commercializing its proprietary immuno-oncology therapies, which are sold to healthcare providers and institutions. Additionally, the company may engage in licensi...
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 122.83M | 74.15M | 386.00K | 5.69M | 13.81M |
| Gross Profit | 122.83M | 74.15M | 7.70M | 5.69M | 13.81M |
| EBITDA | -300.82M | -295.63M | -355.35M | -384.49M | -718.88M |
| Net Income | -302.68M | -315.86M | -379.46M | -402.89M | -732.95M |
Balance Sheet | |||||
| Total Assets | 771.24M | 922.00M | 874.59M | 839.98M | 892.84M |
| Cash, Cash Equivalents and Short-Term Investments | 703.70M | 752.12M | 608.56M | 635.21M | 668.33M |
| Total Debt | 153.72M | 136.36M | 74.77M | 14.62M | 18.54M |
| Total Liabilities | 237.36M | 243.69M | 126.30M | 60.76M | 2.49B |
| Stockholders Equity | 534.62M | 678.90M | 748.29M | 779.22M | -1.60B |
Cash Flow | |||||
| Free Cash Flow | -140.89M | -138.44M | -370.25M | -261.93M | -315.79M |
| Operating Cash Flow | -136.13M | -128.03M | -367.55M | -238.71M | -190.54M |
| Investing Cash Flow | 42.88M | 37.95M | -294.85M | 49.00K | -108.72M |
| Financing Cash Flow | 253.48M | 258.93M | 331.04M | 179.38M | 793.03M |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Technical Analysis
Neutral
6.15
Price Trends
4.57
Positive
5.64
Negative
8.65
Negative
Market Momentum
<0.01
Negative
51.32
Neutral
56.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1541, the sentiment is Neutral. The current price of 6.15 is above the 20-day moving average (MA) of 4.77, above the 50-day MA of 4.57, and below the 200-day MA of 8.65, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.32 is Neutral, neither overbought nor oversold. The STOCH value of 56.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1541.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$25.94B | 42.36 | 15.32% | ― | 48.38% | ― | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
41 Neutral | HK$3.88B | -10.14 | -32.79% | ― | 29639.67% | 23.30% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
4.75
-0.10
-2.06%
HK:1672
Ascletis Pharma, Inc.
16.98
11.88
232.94%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.73
79.82%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
63.50
51.28
419.64%
HK:2616
CStone Pharmaceuticals
9.35
7.13
321.17%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.51
-17.79%
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Corporate Events
ImmuneOnco Nears Interim Milestone in Phase III Trial of Lead CD47 Drug IMM01
Jan 21, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported progress in its late-stage clinical program for IMM01 (Timdarpacept), an innovative CD47-targeting SIRPα-Fc fusion protein and the company’s core product, which has been enginee...
ImmuneOnco Wins NMPA Nod to Test Lead CD47 Drug IMM01 in Atherosclerosis
Jan 12, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has received approval from China’s National Medical Products Administration to initiate a clinical trial of its core drug candidate IMM01 (Timdarpacept) for the treatment of atherosclerosis, mark...
ImmuneOnco Reclaims Global Rights to Key Immuno-Oncology Assets IMM2510 and IMM27M
Jan 6, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has terminated its License and Collaboration Agreement with Axion Bio, Inc., resulting in the reversion of all global development and commercialization rights for its oncology drug candidates IMM2510 a...
ImmuneOnco CEO Increases Stake, Signaling Confidence in Growth
Dec 3, 2025
ImmuneOnco Biopharmaceuticals announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 50,000 H shares in the open market. This move reflects Dr. Tian’s confidenc...
ImmuneOnco’s Phase III Study of Innovative Lymphoma Treatment Approved
Nov 27, 2025
ImmuneOnco Biopharmaceuticals has received approval from the Center for Drug Evaluation of the National Medical Products Administration for its Phase III clinical study protocol of IMM0306, a bispecific molecule for treating relapsed/refractory fo...
ImmuneOnco Redeems and Subscribes to Wealth Management Products
Nov 20, 2025
ImmuneOnco Biopharmaceuticals has announced the redemption of two wealth management products totaling HK$93,323,273 from Huatai Financial, resulting in an estimated unaudited gain of HK$4,730,000. The company has also subscribed to a new wealth ma...
ImmuneOnco Biopharmaceuticals Updates Articles Following Share Placement
Nov 17, 2025
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced amendments to its Articles of Association following the completion of a placement of new H shares, which increased the company’s total issued shares. This adjustment in the share ca...
ImmuneOnco CEO Increases Shareholding, Signaling Confidence in Growth
Nov 7, 2025
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 50,000 H shares on the open market. This purchase reflects Dr. Ti...
ImmuneOnco Advances in Cancer Immunotherapy with New Clinical Trial Milestone
Oct 23, 2025
ImmuneOnco Biopharmaceuticals has successfully dosed the first patient in a Phase IB/II clinical trial for its cancer treatment combination of IMM2510 and IMM01, marking a significant milestone in cancer immunotherapy. This development could enhan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.